CASP3 and osteogenesis imperfecta: Furthermore, we have also shown that the treatment in vitro of mature osteoclasts with neridronate, a bisphosphonate currently used for OI management, leads to the increased production of CK-BB together with a decrease in osteoclast number that is linked to the caspase-3 release due to the activation of the apoptotic process.